Projects per year
Personal profile
Education
- 2012 PhD, Institute of Clinical Medicine, National Cheng Kung University
Experience
- 2024.8- Distinguished Professor, National Cheng Kung University (NCKU)
- 2023.8- Director, Institute of Clinical Medicine, NCKU
- 2023.8- Director, Clinical Medicine Research Center, National Cheng Kung University Hospital, College of Medicine, NCKU
- 2021.8- Professor, Institute of Clinical Medicine, NCKU
- 2021.8- Joint Appointment Professor, Departments of Oncology & Internal Medicine, National Cheng Kung University Hospital, College of Medicine, NCKU
- 2020.10- Attending Physician, Department of Oncology, National Cheng Kung University Hospital, College of Medicine, NCKU
- 2020.8-2023.7 Deputy Director, Cancer Center, National Cheng Kung University Hospital, College of Medicine, NCKU
- 2017.8-2021.7 Associate Professor, Institute of Clinical Medicine, NCKU
- 2015.8-2017.7 Assistant Professor, Institute of Clinical Medicine, NCKU
- 2007.8-2015.7 Clinical Lecturer/Clinical Assistant Professor, Department of Oncology, National Cheng Kung University Hospital, College of Medicine, NCKU
- 2005.7-2020.9 Attending Physician, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, NCKU
- 1999.7-2005.6 Rotating Intern and Resident, National Taiwan University Hospital, College of Medicine, National Taiwan University
Research Interests
- Medical Oncology
- Anti-Cancer Pharmacology
- DNA repair and Ant-oxidant defense mechanism
- Molecular Chemo-resistance
- Impact of nanoplatform on tumor microenvironment
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 2 Zero Hunger -
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics where Wen-Pin Su is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
To Explore the Impact of Intrinsic Sparc via Rab37-Mediated Exocytosis on Lung Cancer Microenvironment, Focusing on Tumor Cells and Macrophages
Su, W.-P. (PI)
26-08-01 → 27-07-31
Project: Research project
-
To Elucidate How the Metallic Nanoplatform Modulates Tumor Microenvironment via Ferroptosis and Develop Novel Treatment Strategy in Young-Onset Pancreatic Cancer( I )
Su, W.-P. (PI)
26-08-01 → 27-07-31
Project: Research project
-
Developing Nanotechnology-Based Approaches for Targeting Tumor Microenvironment by Using Dual Marco and Folate Receptor Β Guided Mivebresib-Loaded Mesoporous Silica Nanoparticles with Anti-Pd-1 Ab to Improve the Efficiency of Pancreatic Cancer Treatment( III )
Su, W.-P. (PI)
25-08-01 → 26-07-31
Project: Research project
-
To Explore the Impact of Intrinsic Sparc via Rab37-Mediated Exocytosis on Lung Cancer Microenvironment, Focusing on Tumor Cells and Macrophages
Su, W.-P. (PI)
25-08-01 → 26-07-31
Project: Research project
-
Developing Nanotechnology-Based Approaches for Targeting Tumor Microenvironment by Using Dual Marco and Folate Receptor Β Guided Mivebresib-Loaded Mesoporous Silica Nanoparticles with Anti-Pd-1 Ab to Improve the Efficiency of Pancreatic Cancer Treatment( II )
Su, W.-P. (PI)
24-08-01 → 25-07-31
Project: Research project
-
Corrigendum to “Synergistic effect of repurposed mitomycin C in combination with antibiotics against Aeromonas infection: In vitro and in vivo studies” [Journal of Microbiology, Immunology and Infection 58 (2025) 189–197, (S1684118224002317), (10.1016/j.jmii.2024.12.005)]
Yeh, C. F., Chen, C. C., Lai, C. C., Liu, J. W., Tang, H. J. & Su, W. P., 2026 Jun, In: Journal of Microbiology, Immunology and Infection. 59, 3, p. 423 1 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
KEYMAKER-U04 substudy 04B: First-line (1L) enfortumab vedotin (EV) plus pembrolizumab (pembro)-based immune checkpoint inhibitor (ICI) combinations for advanced urothelial cancer (UC).
Van Der Heijden, M. S., Sarfaty, M., Caglevic, C., Gross-Goupil, M., Rosenbaum, E., Lee, J. L., Powles, T., Sridhar, S. S., Rojas, C., Shin, S. J., Robbrecht, D. G. J., Puente, J., Morales-Barrera, R., Su, W. P., Su, Y. L., Maillet, D., Wang, A., Bavle, A. A., Homet Moreno, B. & Peer, A., 2026 Mar, In: Journal of Clinical Oncology. 44, p. 634 1 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Myeloid-derived suppressor cells-guided mesoporous silica nanoplatform delivering a BET inhibitor exerts anticancer effects by reprogramming the immunosuppressive tumor microenvironment
Chang, L. C., Xu, L., Liu, Y. F., Lin, C. A., Wu, S. H. & Su, W. P., 2026 Sept 1, In: Chemical Engineering Journal. 543, 178042.Research output: Contribution to journal › Article › peer-review
Open Access -
Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma
Kikuchi, E., Van der Heijden, M. S., Valderrama, B. P., Gupta, S., Bedke, J., Shin, S. J., Li, J. R., Guo, J., Danchaivijitr, P., Kanesvaran, R., Park, S. H., Su, W. P., Kandori, S., Bae, W. K., Wong, A., Gorla, S., Bavle, A., Yu, X., Lu, Y. T. & Powles, T., 2026 Mar, In: International Journal of Clinical Oncology. 31, 3, p. 436-446 11 p.Research output: Contribution to journal › Article › peer-review
Open Access6 Link opens in a new tab Citations (Scopus) -
Synergistic activity of mitomycin C in combination with ciprofloxacin against severe Vibrio vulnificus infection
Yeh, C. F., Chen, C. C., Lai, C. C., Hsu, P. Y., Liu, J. W., Tang, H. J. & Su, W. P., 2026, (Accepted/In press) In: Journal of Microbiology, Immunology and Infection.Research output: Contribution to journal › Article › peer-review
Open Access